POST Online Media Lite Edition



 

Shire completes acquisition of NPS Pharma

Staff writer |
Shire plc announced the completion of the tender offer for all of the outstanding shares of NPS Pharmaceuticals, Inc. and the subsequent acquisition of NPS Pharma

Article continues below






The tender offer expired at 12:00 midnight, New York City time, at the end of Friday, February 20, 2015, and was not extended.

As of the expiration of the tender offer, a total of approximately 88,869,118 common shares of NPS Pharma (excluding 7,599,694 common shares of NPS Pharma guaranteed to be delivered within the next three NASDAQ trading days) had been validly tendered and not withdrawn pursuant to the tender offer, representing approximately 81.7% of the outstanding common shares of NPS Pharma.

All shares that were validly tendered and not withdrawn pursuant to the tender offer were accepted for payment.

After the acceptance of shares that were validly tendered and not withdrawn pursuant to the tender offer, Shire completed the acquisition of NPS Pharma today through a merger of one of Shire's subsidiaries with and into NPS Pharma.

In connection with the merger, all common shares of NPS Pharma that were not accepted for payment in the tender offer excluding certain were converted into the right to receive $46 per share in cash, without interest and less any applicable withholding taxes, the same price that will be paid for shares accepted for payment in the tender offer.

Following completion of the merger, NPS Pharma became a wholly owned subsidiary of Shire and NPS Pharma's shares ceased to be traded on NASDAQ.


What to read next

Shire plc to buy Meritage Pharma in $70m + milestones deal
Shire completes $5.9 billion acquisition of Dyax
Shire received better proposal from AbbVie